Cargando…

Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

BACKGROUND: Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping informatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jorgensen, Andrea L., Prince, Clare, Fitzgerald, Gail, Hanson, Anita, Downing, Jennifer, Reynolds, Julia, Zhang, J. Eunice, Alfirevic, Ana, Pirmohamed, Munir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454722/
https://www.ncbi.nlm.nih.gov/pubmed/30961588
http://dx.doi.org/10.1186/s12916-019-1308-7
_version_ 1783409596577087488
author Jorgensen, Andrea L.
Prince, Clare
Fitzgerald, Gail
Hanson, Anita
Downing, Jennifer
Reynolds, Julia
Zhang, J. Eunice
Alfirevic, Ana
Pirmohamed, Munir
author_facet Jorgensen, Andrea L.
Prince, Clare
Fitzgerald, Gail
Hanson, Anita
Downing, Jennifer
Reynolds, Julia
Zhang, J. Eunice
Alfirevic, Ana
Pirmohamed, Munir
author_sort Jorgensen, Andrea L.
collection PubMed
description BACKGROUND: Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping information (‘POCT-GGD’ approach) led to improved anticoagulation control. To determine whether this approach could translate into clinical practice, we undertook an implementation project using a matched cohort design. METHODS: At three clinics (implementation group; n = 119), initial doses were calculated using the POCT-GGD approach; at another three matched clinics (control group; n = 93), patients were dosed according to the clinic’s routine practice. We also utilised data on 640 patients obtained from routinely collected data at comparable clinics. Primary outcome was percentage time in target INR range. Patients and staff from the implementation group also provided questionnaire feedback on POCT-GGD. RESULTS: Mean percentage time in INR target range was 55.25% in the control group and 62.74% in the implementation group; therefore, 7.49% (95% CI 3.41–11.57%) higher in the implementation group (p = 0.0004). Overall, patients and staff viewed POCT-GGD positively, suggesting minor adjustments to allow smooth implementation into practice. CONCLUSIONS: In the first demonstration of the implementation of genotype-guided dosing, we show that warfarin dosing determined using an algorithm incorporating genetic and clinical factors can be implemented smoothly into clinic, to ensure target INR range is reached sooner and maintained. The findings are like our previous randomised controlled trial, providing an alternative method for improving the risk-benefit of warfarin use in daily practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1308-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6454722
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64547222019-04-19 Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study Jorgensen, Andrea L. Prince, Clare Fitzgerald, Gail Hanson, Anita Downing, Jennifer Reynolds, Julia Zhang, J. Eunice Alfirevic, Ana Pirmohamed, Munir BMC Med Research Article BACKGROUND: Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping information (‘POCT-GGD’ approach) led to improved anticoagulation control. To determine whether this approach could translate into clinical practice, we undertook an implementation project using a matched cohort design. METHODS: At three clinics (implementation group; n = 119), initial doses were calculated using the POCT-GGD approach; at another three matched clinics (control group; n = 93), patients were dosed according to the clinic’s routine practice. We also utilised data on 640 patients obtained from routinely collected data at comparable clinics. Primary outcome was percentage time in target INR range. Patients and staff from the implementation group also provided questionnaire feedback on POCT-GGD. RESULTS: Mean percentage time in INR target range was 55.25% in the control group and 62.74% in the implementation group; therefore, 7.49% (95% CI 3.41–11.57%) higher in the implementation group (p = 0.0004). Overall, patients and staff viewed POCT-GGD positively, suggesting minor adjustments to allow smooth implementation into practice. CONCLUSIONS: In the first demonstration of the implementation of genotype-guided dosing, we show that warfarin dosing determined using an algorithm incorporating genetic and clinical factors can be implemented smoothly into clinic, to ensure target INR range is reached sooner and maintained. The findings are like our previous randomised controlled trial, providing an alternative method for improving the risk-benefit of warfarin use in daily practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1308-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-08 /pmc/articles/PMC6454722/ /pubmed/30961588 http://dx.doi.org/10.1186/s12916-019-1308-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jorgensen, Andrea L.
Prince, Clare
Fitzgerald, Gail
Hanson, Anita
Downing, Jennifer
Reynolds, Julia
Zhang, J. Eunice
Alfirevic, Ana
Pirmohamed, Munir
Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
title Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
title_full Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
title_fullStr Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
title_full_unstemmed Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
title_short Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
title_sort implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three uk clinics: a matched cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454722/
https://www.ncbi.nlm.nih.gov/pubmed/30961588
http://dx.doi.org/10.1186/s12916-019-1308-7
work_keys_str_mv AT jorgensenandreal implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT princeclare implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT fitzgeraldgail implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT hansonanita implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT downingjennifer implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT reynoldsjulia implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT zhangjeunice implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT alfirevicana implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy
AT pirmohamedmunir implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy